A CLINICAL STUDY ON AMLAPITTA AND ITS MANAGEMENT WITH CHHINNODBHAVADI GHANAVATI by Nibedita, Mohapatra et al.
ISSN: 2322 - 0902 (P) 
ISSN: 2322 - 0910 (O) 
 IJAPR | December 2015 | Vol 3 | Issue 12   43 
International Journal of Ayurveda  
and Pharma Research 
 
Research Article 
 
 
A CLINICAL STUDY ON AMLAPITTA AND ITS MANAGEMENT WITH CHHINNODBHAVADI 
GHANAVATI 
Mohapatra Nibedita1, Biswal Debasis1, Murthy Seema Krishna2, Sharma Vishnu Dutt3, Arawatti 
Siddaram4* 
1Assistant Professor, PG Dept. of Kaya Chikitsa, Major S.D.Singh P.G.Ayurvedic Medical College, Farrukhabad. UP. 
2Assistant Professor, PG Dept. of Prasuti Tantra and Stree Roga, Major S.D.Singh P.G.Ayurvedic Medical College, 
Farrukhabad. UP.  
3Assistant Professor, PG Dept. of Shalya Tantra, University College of Ayurveda, Dr.S.R.R.A.U., Jodhpur. Rajasthan.   
*4Assistant Professor, PG Dept. of Shalya Tantra, Major S.D.Singh P.G.Ayurvedic Medical College, Farrukhabad. UP.  
ABSTRACT 
Amlapitta is a disease prevalent all over the world. The increasing prevalence rate is a constant challenge 
to the research workers. The disease Amlapitta is a common functional disease of Annavaha srotas. 
Materialistic life style provokes people to run behind a busy, stressful life with least concern towards 
proper food habit. The aim of the present study was to find out efficacy of Chhinnodbhavadi Ghanavati in 
comparison to modern PPI. In present study total 40 patients were taken, divided into 2 equal groups. In 
group-I: 20 patients were treated with oral administration of trial drug that is Chhinnodbhavadi 
ghanavati 500mg 2 tab twice a day for 45 days and in group-II: 20 patients were treated with control 
drug that is pantoprazole 40mg 1 tab once a day orally for 45 days. After conducting clinical trial on 40 
patients, observation and results were obtained. Statistical analysis shows that both trail and control 
drug were significantly effective to reduce the cardinal symptoms. As compared to trail drug the effect of 
control drug is better to reduce symptoms. However as compared to side effects and contra-indications of 
the control drug, it is advisable to use Chhinnodbhavadi Ghanavati for the treatment of Amlapitta for a 
long period. 
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INTRODUCTION
Ayurveda, the most ancient science of the world, 
considered as Upaveda (subsidiary) of Atharva Veda, has 
taken rapid stride over the last few decades in realizing 
people probe into basics of physical and psychological 
health related problems of fast changing life styles. 
Change is the unchanged law of the universe. Theory of 
evolution talks about the Survival for the fittest. Human 
being need to go for short term or long term adaptation 
to survive in this world. Irregular and improper food 
habits, busy stressful lifestyle and westernization are the 
main culprits of an Obstinate disorder escalating in its 
prevalence i.e. Amlapitta1. This is a burning problem of 
the society. 
As the new era is progressing, human needs are 
rising proportionately in a higher ratio due to 
introduction of newer technology through research. But 
in this fast food era human being forgets everything to 
achieve their goal. No gain without pain, for that he need 
a faceoff with hurry, worry, stress, strain, anxiety, 
improper food habit2. All of them accelerate the vitiation 
of dosha by disturbing action of Agni3. 
Change in function of Agni leads to various 
diseases. It is common for many of us to face a burning 
sensation in stomach and chest at times. This is in most 
cases due to excessive secretion of acidic material in the 
stomach. In Ayurvedic terminology, this is referred as 
Amlapitta, where vitiation of Pitta Dosha occurs along 
with Kapha Dosha3. 
This disease was not described in any text of the 
Brihatrayi but a condition named as “Vidagdha Jirnna” 
can be compared with Amlapitta. The Amlapitta is an 
established entity from the time of Madhav the famous 
writer of the book “Madhav Nidan” (Rogavinischaya)1. 
Among the three Doshas, Pitta plays a key role for the 
genesis of Amlapitta. Improper digestion of Amla rasa 
gives rise to Amlapitta. This is a mohakari4 (confusing) 
disease, which gives up different sign and symptoms in 
various persons. If we can treat Agni we can do a great 
favour to society. 
In a demographic survey, its prevalence range 
observed is about 11% to 38.8% of world population. 
Malaysia, Mexico, Spain and Yemen reported figures on 
the top quartile of prevalence, whereas the Asian 
countries reported prevalence rates in the lowest 
quartile. It is reported that 7.6% of Indian subjects have 
significant GERD symptoms5. Rapid socioeconomic 
development and the westernization of Asian lifestyles, 
including changes in diet and an increase in average 
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body mass index, are likely to be the key factors in 
change in epidemiology. 
NEED OF STUDY 
Hence taking into consideration of its severity 
and rampart occurrences a combination named as 
“Chhinnodbhavadi Ghanavati” was taken to prove its 
efficacy for the satisfactory management of Amlapitta. 
Chhinnodbhavadi kwath6 (decoction) consists of equal 
proportion of Terminalia chebula Retz, Terminalia 
belerica Roxb, Emblica officinalis Gaertn, Tinospora 
cordifolia (Willd), Azadirachta indica A juss and 
Trichosanthus dioica Roxb. Coarse powder of these drugs 
will be converted to Ghanavati form from the decoction 
for enteral administration (of the drug) with honey with 
special reference to Chakradutta (52/17) and Bhaisajya 
ratnavali (56/17). Guduchi7 has antiulcer and antioxidant 
activity. Neem8 is regularly taken to correct problems 
with in the stomach and bowels. It promotes a healthy 
digestive system by protecting the stomach, aiding in the 
elimination and removal of toxins and harmful bacteria. 
Haritaki9 maintains the gut transit time. Bhibhitaki10 is a 
stomachic and cholagogue by nature. Amalaki11 is a 
cholagogue, antioxidant and protective by nature. Patol12 
Leaves are cholagogue, aperients, tonic, febrifuge, 
expectorant, alterative and used in cases of enlarged liver 
and spleen, hemorrhoids, fistula-in-ano, intrinsic 
hemorrhage, Erysipelas diseases of mouth, 
inflammations and wounds. As it consists of six drugs 
and all of them will full fill the requirement to treat the 
Amlapitta (GERD) which will give relief to the patient 
that’s why the drug has been selected for this research 
work. 
Aims and Objectives 
The study was conducted with the following objectives.  
1. To compare the efficacy of the trial drug with control 
drug.  
2. To compare the trend of recovery of both the groups. 
DRUG REVIEW 
Criteria for selection of “Chhinnodbhavadi ghanavati” 
as the trial drug 
A) The drug is purely herbal. 
B) All the ingredients are easily available and cheap. 
C) It is suitable for oral administration.  
D) All the drugs are Pittasamaka in nature and Guduchi 
is an immunomodulator. 
Physical Analysis of trial drug 
Colour – Black 
Odor – Aromatic  
Taste – Astringent, Sweet, Sour, Salty and Bitter 
Table 1: Ingredients of Chhinnodbhavadi ghanavati 6: 
S.No Drug Botanical name Part used Quantity 
1 Guduchi Tinospora cordifolia wild Stem 1 part 
2 Nimba Azadirachta indica A juss Bark 1 part 
3 Patola Trichosanthus dioica Roxb Whole plant 1 part 
4 Amalaki Emblica officinalis Gaertn Fruit 1 part 
5 Vibhitaki Terminalia belerica Roxb Fruit 1 part 
6 Haritaki Terminalia chebula Retz Fruit 1 part 
Method of preparation of Chhinnodbhavadi 
ghanavati  
 All the above 6 drugs were taken in equal 
quantity in Coarse powder form (Yavakuta churna) and 
mixed thoroughly. Then the drugs were cooked in about 
16 times of water. The resulting solution was then sieved 
through a cloth again brewed until it became thick. The 
thick solution then dried in sunlight. The dried solution 
was then made into Ghanavati form. 
MATERIALS AND METHODS  
 The present clinical study was conducted in P.G 
Dept. of Kayachikitsa, G.A.M Puri. In this study total 
number of 47 patients was registered for the research 
work and the patients were collected from both O.P.D 
and I.P.D of hospital attached to the G.A.M Puri based on 
the criteria of selection.  
Source of Data  
 Literary Data: Taken from various Ayurvedic 
Samhitas, Text books, Journals, magazine’s articles and 
also from various conferences. 
Clinical Data: were taken from O.P.D and I.P.D of G.A.M 
Puri irrespective of age, sex, religion, socioeconomic 
status etc. 
STUDY DESIGN  
Patients diagnosed with Amlapitta were selected 
from the O.P.D. & I.P.D. of GAM&H , Puri in a random 
manner. Basing on the screening, investigation and 
taking consent from them, the diagnosed cases were 
registered for the study in a prescribed case sheet. Out of 
47 registered patients, Forty (40) patients (20 patients in 
Grade– 1 and 20 patients in Grade-2) completed therapy 
and 7 patients left the treatment schedule between the 
therapies, which were counted as dropout cases. The 
study was carried out from May 2013 to October 2013.  
The case selection for trial was according to the 
following criteria 
INCLUSION CRITERIA  
1. Age-20 to 60 yrs  
2. Both sexes  
3. Mentally stressed and strained  
4. Spicy and oily food in takers 
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5. Patients with classical symptoms of Amlapitta. 
6. Patients who were co-operative and ready give 
written consent. 
EXCLUSION CRITERIA 
1. Below 20yrs and above 60 yrs  
2. Pregnant and lactating  
3. Intestinal Koch’s  
4. Ca stomach  
5. Cholecystitis  
6. Addicted to alcohol  
7. Barrett's oesophagus  
LABOROTORY INVESTIGATION-  
1. TLC 
2. Hb% 
3. FBS 
4. Stool test (RE, ME, OBT) 
5. Gastric juice base line pH (early morning) 
6. Endoscopy  
Table 2: Showing Grouping and Management 
Group Trial (20 cases) Control (20 cases) 
Drug Chhinnodbhavadi 
ghanavati 
pantoprazole 
Dose 500mg 2 tab bd 40 mg 1 tab OD 
Duration 45 days 45 days 
The trial drug was prepared in the Department of 
Rasasastra and Bhaisajya Kalpana, G.A.M. Puri with the 
approval of IEC (Institutional Ethical Committee). 
DIET TO ADVICE – Strictly advised to avoid salty, spicy 
and stale food. 
Study design- TG1 (BT) Vs TG1 (AT) –effectiveness of 
treatment group-1 will be assessed. 
 TG2 (BT) Vs TG2 (AT) –effectiveness of treatment group-
2 will be assessed. 
N.B. - BT – Before treatment AT – After treatment 
Follow up 
 Patients were followed up after 15 days, 30 days 
and 45 days. 
 All the investigations were done in empty stomach. 
 Improvements and other effects were noted down. 
 No side effects were reported by any individual 
during trial. 
ASSESSMENT 
The assessment progress was noted after 15 days based 
on the subjective and objective criteria. Grade points 
considering the severity of the sign and symptoms are 
Severity Gradation Grade point 
Normal G0 - 0 
Mild G1 + 1 
Moderate G2 ++ 2 
Severe G3 +++ 3 
 
Subjective Parameters  
1) Avipaka Klama     
2) Utklesha  
3) Vamana 
4) Tiktoamlodgara 
5) Hritkanthadaha  
6) Aruchi 
7) Udarashoola  
Objective Parameters 
1) Gastric juice baseline pH  
2) Endoscopic findings 
 Assessment scale: 
 The symptoms were recorded in terms of clinical 
grades as per the statement of the patients. The different 
gradations were done for different complains as follows: 
1. Avipaka 
G₀ - natural appetite for food after 5- 6 hrs of 
ingestion of mixed Indian food 
G₁ -appetite for food after 7- 8 hrs of taking food 
G₂ - appetite for food after 9 – 10 hrs of taking food 
G₃ - appetite for food after 10 – 12 hrs of taking food 
2. Klama  
G₀ - no tiredness on routine physical work 
G₁ - feeling tiredness on routine physical work 
G₂ - feeling tiredness to do normal routine work 
G₃ - feeling of tiredness to do any work or no interest 
in work 
3. Utklesha 
G₀ - no sensation of vomiting 
G₁ - nausea 1 – 3 times a wk 
G₂- nausea 4 – 7 times a wk 
G₃ - frequent feeling of nausea with or without food 
4. Vamana 
G₀ - no vomiting 
G₁ - occasional 
G₂- 2-3 times a wk 
G₃ - every day 
5. Tiktaamlodgara 
G₀ - no regurgitation of gastric content in to the 
mouth  
G₁ - rare regurgitation of gastric content in to the 
mouth 
G₂ - often regurgitation of undigested food in to the 
mouth 
G₃ - frequent regurgitation of gastric content in to the 
mouth 
6. Aruchi 
G₀ - having good appetite 
G₁ - loss of appetite for breakfast and snacks 
G₂- loss of appetite for breakfast, lunch , dinner 
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G₃ - aversion of any food 
7. Hritkantha daha  
G₀ - no pyrosis 
G₁ - pyrosis in empty stomach  
G₂ - pyrosis in empty stomach as wel as after 3-4 hrs 
of taking meal 
 G₃ - constant or frequent pyrosis 
8. Udarashoola 
G₀ - no pain in the abdomen 
G₁ - mild pain in the abdomen of low intensity 
G₂ -moderate pain causing partial interruption in the 
work  
G₃ - severe pain complete interruption of work 
Gastric juice baseline pH 
G₀ - in a range of >6 
G₁ - in a range of 4-5.9 
G₂ - in a range of 2-3.9 
G₃- in a range of 0-1.9  
Endoscopy 
The severity of esophagitis is commonly classified 
into four grades according to the Los Angeles 
Classification:  
• Grade A----One or more mucosal breaks < 5 mm in 
maximal length 
• Grade B---One or more mucosal breaks > 5mm, but 
without continuity across mucosal folds 
• Grade C---Mucosal breaks continuous between > 2 
mucosal folds, but involving less than 75% of the 
esophageal circumference 
• Grade D---Mucosal breaks involving more than 75% 
of esophageal circumference 
Assessment of Result 
Statistical assessment of results The sign and 
symptoms observed for the study among trial and 
control groups were carefully recorded. The sign and 
symptoms before and after treatment are also recorded. 
The mean ± SD before treatment of each sign and 
symptoms was compared with after 15days, 30 days and 
45 days of treatment in each group. Then the paired t- 
test was used for the purpose of test of significance. The 
effectiveness of the trial and control drug to different 
sign and symptoms of each group were assessed through 
p- value. 
Observation 
Table No: 3- Demographic Observation 
Geographic observation Predominance Percentage No. of patients 
Age 50-60 yrs 32.5% 13 
Sex Females 57.5% 23 
Socio-economic status  Middle class 85% 34 
Onset of disease  Gradual  65% 26 
Incidence of aggravation factors Hunger  62.5% 25 
Incidence of relieving factors Medicines  50% 20 
Addiction Tea 55% 22 
Agni(Digestion capacity) Mandagni (less) 52.5% 21 
Mental status Stressed  37.5% 15 
Prakruti (nature of patient) Pitta Kaphaja 37.5% 15 
Site of Udarshoola Epigastrium  60% 21 
Chronicity <2 year 60% 24 
Nature of Udarshoola Recurrently burning 40% 14 
Family history Present  77.5% 31 
Habitat  Anupa  77.5% 31 
Nature of work Service  37.5% 15 
RESULTS: 
Table 4: Showing the percentage of relief in different sign/ symptoms with the cases of trial and control drug 
(after 45 days of treatment) 
S.No. Sign and Symptoms 
 Trial Group Degree of 
Severity P* 
Control Group Degree 
of Severity 
  
G0 G1 G2 G3 G0 G1 G2 G3 P* 
1 Avipaka 8 4 0 0 80 14 0 1 0 93.1 
2 Klama 12 2 0 0 88.25 7 2 0 0 83.33 
3 Utklesha 7 6 0 0 76 13 3 1 0 82.75 
4 Vamana 3 2 2 0 53.84 8 2 0 0 88.88 
5 Aruchi 12 2 0 0 87.5 8 1 0 0 90.9 
6 Hritkanthadaha 8 3 0 0 72.72 11 0 0 0 100 
7 Tiktoamlodgara 6 4 1 0 75 17 1 0 0 96.55 
8 Udarashoola 8 9 0 0 75 18 0 0 0 100 
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 Table 5: Showing the percentage of change in ph with the cases of trial and control drug (after 45 days of 
treatment) 
S.No. Range  Trial Group P*  Control Group P* 
BT AT BT AT 
1 4 to 5.9 0 2 20.4 0 5 27.65 
2 2 to 3.9 11 17 13 15 
3 0 to 1.9 9 1 7 0 
The percentage of relief in trial group was 20.4% while in control group it is 27.65% after 45 days. 
Table 6: Showing the percentage change of the patients got improvement after treatment with respect to 
different sign and symptoms (group 1) 
S. No. Sign and Symptoms 
Group 1 ( n1= 20) 
AT (15) AT(30) AT(45) 
f % f % F % 
1 Avipaka 1 9.09 7 63.63 11 100 
2 Klama 5 38.38 10 76.92 13 100 
3 Utklesha 4 30.76 7 53.84 12 92.3 
4 Tiktoamlodgara 4 36.36 9 81.81 11 100 
5 Hritkanthadaha 3 42.85 5 71.42 6 85.71 
6 Aruchi 2 14.28 7 50 12 85.71 
7 Vamana 1 14.28 3 42.85 7 100 
8 Udarashoola 3 17.64 14 82.35 17 100 
9 pH - - - - 9 45 
10 Endoscopy - - - - 6 60 
Table 7: Showing the percentage change of the patients got improvement after treatment with respect to 
different sign and symptoms (group2) 
S. No. Sign and Symptoms 
Group 2 n2=20 
AT(15) AT(30) AT(45) 
f % f % f % 
1 Avipaka 8 53.53 13 86.86 15 100 
2 Klama 3 33.33 6 66.66 8 88.88 
3 Utklesha 13 76.47 16 94.11 16 94.11 
4 Tiktoamlodgara 13 72.22 16 88.88 16 88.88 
5 Hritkanthadaha 9 81.81 10 90.9 11 100 
6 Aruchi 2 22.22 8 88.88 9 100 
7 Vamana 4 40 10 100 10 100 
8 Udarashoola 14 77.77 18 100 18 100 
9 pH - - - - 11 100 
10 Endoscopy - - - - 10 100 
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N:B – Clinical assessment is calculated considering the clinical relief in the severity grade details of the grade described 
in the clinical profile.  
Table No: 8- Showing the clinical assessment of results after treatment in different groups 
DISSCUSION  
Though various medicaments are available to 
treat this disease but result is unsatisfactory on long 
term use, due to their adverse effect. Review of research 
work shows that no such clinical research had been 
carried on this typical disease with respect to the present 
trial drug that is “Chhinnodbhavadi ghanavati”. 
Experimental study of this particular trial drug had been 
carried on stress induced ulcer on Albino rats and no 
toxicity was reported in the study (MB Nariya et al) 
which inspires the researcher to conduct a clinical study 
on this particular drug. Hence in this study 
“Chhinnodbhavadi ghanabvati” (ref- Chakradutta 
Amlapitta prakarana) has been selected as the trial drug 
consisting of six different drugs in equal amount. All the 
six drugs are Pittasamaka and Deepan in nature. In 
various studies it was reported that Guduchi acts as an 
antacid, Medhya (anti stress activity) and also 
immunomodulator which strengthens the mucosal 
defence mechanism. About Nimba, it has direct impact on 
H+K+ ATPase inhibition. Patola patra is stomachic and 
cholagogue in nature, while Triphala increases gut 
transit time or gastric motility. Madhu13 (honey) is taken 
as Anupana which is Madhura in rasa and Kasaya in 
Anurasa, Anushnasheeta veerya and Pittasamaka in 
nature. It also creates coating on the mucosal surface. 
Acharya Madhav1 described this disease as a 
separate chapter and Acharya Kashyap14 described it 
with its management. Amlapitta is a Pitta predominant 
Vata, Kapha disease. The cardinal features of Amlapitta 
are Avipaka, Klama, Utklesha, Tiktoamlodgara, Gaurava, 
Aruchi, Hritkanthadaha. With the trial drug, there was a 
symptomatic relief in the patients i.e. improvement in 
Avipaka, Tikta Amla Udgara, Hridakanthadaha, Utklesha, 
Aruchi, Vamana and Udarashoola. A comparative gastric 
pH and endoscopy before and after the treatment 
showed that the trial drug increases the base line pH of 
the gastric juice as well as strengthen the mucosal 
defense mechanism.  
Out of 20 patients of Amlapitta (GERD) treated 
with trial drug, 40 % patients had shown maximum 
improvement and 55% patients were moderately 
improved. This implies that Chhinnodbhavadi ghanavati 
may be considered as an effective drug for Amlapitta 
(GERD). As Amlapitta (GERD) is a chronic condition it 
needs a long period study. Statistically it has been 
observed that the trial drug is significantly effective to 
reduce all the sign and symptoms of Amlapitta. 
CONCLUSION  
 From this study it is revealed that though both 
the drugs are significantly effective in Amlapitta but 
control drug is highly significant in comparison to trial 
drug. 
Scope of further study 
• This trial was a time bound limited study of 45 days 
so an extended long term trial is required comparing 
both the drugs for better comparison. 
• The cost of trial drug can brought down by massive 
production. 
• Since the recurrence rate of GERD after PPI 
treatment is significant so an extension of trial to 
include the recurrence rate may show better efficacy 
of trial drug.  
• The mode of action of the drug is not clear as such. It 
needs a further study.  
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